Aquinox discards lead drug, chops half of its staff in wake of PhIII disaster

When Aquinox conceded utter failure on its Phase III trial two weeks ago, execs were clear that there was nothing left to salvage. They are now concluding that more than half of the staff will have to go with the drug program